**Core tip:** The 8^th^ edition American Joint Committee on Cancer TNM criteria for pancreatic cancer emphasize the tumor size cutoff point of 4 cm for the first time. Thus we used the Surveillance Epidemiology and End Results database, a population-based database, to evaluate the new changes in pancreatic cancer staging and the prognostic factors of stage IB and IIA pancreatic cancer.

INTRODUCTION
============

Pancreatic cancer is an aggressive and devastating disease, which is characterized by invasiveness, rapid progression, and profound resistance to treatment\[[@B1]-[@B3]\]. The incidence of pancreatic cancer in the United States and western Europe is 10/100000 per year and almost approaches mortality\[[@B4]\]. The overall survival rate at 5 years is less than 5%\[[@B5],[@B6]\]. Surgical resection is still the only treatment providing prolonged survival; however, even after a curative resection, the 5-year survival rate remains low\[[@B7]\].

Tumor size is the basis of cancer staging, which is one of the strongest prognostic factors in various cancers, including pancreatic cancer\[[@B8]-[@B10]\]. Compared with the 6^th^ and 7^th^ edition of the American Joint Committee on Cancer (AJCC) system for defining stage IB pancreatic cancer (IB: tumor diameter \> 2 cm, no regional lymph node metastasis, no distant metastasis)\[[@B11]\], the 8^th^ edition AJCC criteria emphasize the cutoff point of 4 cm (IB: tumor diameter \> 2 but ≤ 4 cm; IIA: tumor diameter \> 4 cm, both with no regional lymph node metastasis and no distant metastasis)\[[@B12],[@B13]\]. Clinically, the size and location of pancreatic tumor determine the type of surgical resection\[[@B14]-[@B16]\], which suggests the important role of tumor size and location. Therefore, the aim of this study was to evaluate the changes in the AJCC system for defining stage IB and IIA pancreatic cancer and identify their prognostic factors.

MATERIALS AND METHODS
=====================

Patients
--------

The Surveillance Epidemiology and End Results (SEER) database (1973-2013) was used for the study. The National Cancer Institute's SEER\*Stat software (Version 8.2.0) was used to identify patients. All patients underwent surgical treatment and had a pathologically confirmed diagnosis of stage IB pancreatic tumor according to the 6^th^ and 7^th^ edition of the AJCC criteria. Patients with unknown tumor size were excluded. Demographics, including age, gender, and race, were retrieved. Tumor variables included location of the primary tumor, tumor size, and grade. Survival data were extracted at 1 mo intervals for a follow-up period between 1 mo and 110 mo.

Statistical analysis
--------------------

The enrolled patients were divided into two groups based on tumor size according to the 8^th^ edition AJCC criteria (IB: tumor diameter \> 2 but ≤ 4 cm, IIA: tumor diameter \> 4 cm). The independent *t*-test and the *χ*^2^ test were used for the difference analysis between the two groups. Univariate analysis with the log-rank test and multivariate analysis with the Cox proportional hazards regression model were performed to explore the difference in prognostic factors between the two groups, with *P* values \< 0.05 considered statistically significant. All analyses were performed using SPSS software, version 13.0 for Windows.

RESULTS
=======

A total of 1349 pancreatic cancer patients were selected from the SEER database. The age of the patients ranged from 18 to 90 years, with a median age of 65 years. There were 626 male patients and 723 female patients. The median tumor diameter was 43.4 mm (range, 21-540 mm). The pathological stage was classified as IB in 886 patients and IIA in 463 patients, according to the AJCC 8^th^ criteria. The total median survival of these patients was 62 mo, and their 1-, 3-, and 5-year survival rates were 83.8%, 58.9%, and 50.6%, respectively. The patients' clinical characteristics are presented in Table [1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the entire patient cohort[1](#T1FN1){ref-type="table-fn"} *n* (%)

  **Characteristic**              **Entire cohort**   **Stage IB**   **Stage IIA**   ***P* value**
  ------------------------------- ------------------- -------------- --------------- ---------------
  Number of patients              1349                886            463             
  Age (yr), median (range)        65 (18-90)          65 (18-90)     63 (18-90)      0.000
  Tumor size (mm), mean (range)   43.4 (21-540)       29.5 (21-40)   70.0 (41-540)   0.000
  Gender                                                                             
  Male                            626 (46.40)         405 (45.71)    221 (47.73)     0.480
  Female                          723 (53.60)         481 (54.29)    242 (52.27)     
  Primary site                                                                       
  Head                            633 (46.9)          486 (54.85)    147 (31.75)     0.000
  Body                            165 (12.23)         103 (11.6)     62 (13.39)      
  Tail                            350 (25.95)         186 (20.99)    164 (35.21)     
  Other                           201 (14.90)         111 (12.53)    90 (19.44)      
  Grade                                                                              
  I                               348 (25.80)         221 (24.94)    127 (27.43)     0.006
  II                              484 (35.88)         335 (37.81)    149 (32.18)     
  III                             230 (17.05)         164 (18.52)    66 (14.25)      
  IV                              17 (1.26)           10 (1.13)      7 (1.51)        
  Unknown                         270 (20.01)         156 (17.61)    114 (24.62)     
  Race                                                                               
  White                           1060 (78.58)        694 (78.33)    366 (79.05)     0.760
  Other                           289 (21.42)         192 (21.67)    97 (20.95)      

Factors were compared by independent *t* test and *χ*^2^ test for continuous and categorical variables, respectively.

Under the new criteria, the median tumor diameter of stage IB patients was 29.5 mm, while the median tumor diameter of stage IIA patients was 70.0 mm. The primary site of 54.85% of stage IB tumors was the head of the pancreas, while the primary site of stage IIA tumors was mainly the tail and head of the pancreas (35.21% and 31.75%, respectively). Among both stage IB and IIA patients, the majority (approximately 60%) were in grade I and II.

Univariate survival analysis of clinical characteristics was evaluated with a log-rank test (Table [2](#T2){ref-type="table"}). Age, grade and primary site were significantly associated with the overall survival of stage IB patients (*P* \< 0.05), while gender and race showed no significant association with survival (*P* \> 0.05). For stage IIA patients, age, gender, grade, and primary site were significantly associated with overall survival (*P* \< 0.05), but race showed no significant association with survival (*P* \> 0.05). Multivariate analyses for stage IB and IIA patients were performed with the Cox regression model (Table [3](#T3){ref-type="table"}). The results indicated that for stage IB patients, age and primary site were the independent prognostic factors; for stage IIA patients, age and grade were the independent prognostic factors (*P* \< 0.05). Overall, the survival time of stage IB and IIA patients had no significant difference (Figure [1A](#F1){ref-type="fig"}); whereas, for both stage IB and IIA, the risk of death was lower for patients aged ≤ 65 years than those aged \> 65 years (Figure [1B](#F1){ref-type="fig"}).

![Kaplan-Meier analysis of overall survival. A: Among 1349 patients, the survival time of stage IB and IIA patients had no significant difference (*P* \> 0.05); B: For both stage IB and IIA, death risk was lower in patients aged ≤ 65 yr than those aged \> 65 yr.](WJG-23-2757-g001){#F1}

###### 

Prognostic significance for overall survival by univariate analysis of variables for stage IB and IIA patients[1](#T2FN1){ref-type="table-fn"}

  **Variable**      **Stage IB**   **Stage IIA**           
  ----------------- -------------- --------------- ------- -------
  Age (yr)                                                 
  ≤ 65              444            0.000           270     0.000
  \> 65             442            193                     
  Gender                                                   
  Male              405            0.162           221     0.002
  Female            481            242                     
  Tumor size (mm)                                          
  21-30             584            0.258                   
  31-40             302                                    
  41-70                            332             0.013   
  \> 70             131                                    
  Primary site                                             
  Head              486            0.000           147     0.004
  Body              103            62                      
  Tail              186            164                     
  Other             111            90                      
  Grade                                                    
  I                 221            0.000           127     0.000
  II                335            149                     
  III               164            66                      
  IV                10             7                       
  Unknown           156            114                     
  Race                                                     
  White             694            0.148           366     0.685
  Other             192            97                      

Univariate analysis was done by Kaplan-Meier method.

###### 

Prognostic significance for overall survival by multivariate analysis of variables for stage IB and IIA patients[1](#T3FN1){ref-type="table-fn"}

  **Variable**                         **Stage IB**   **Stage IIA**                                 
  ------------------------------------ -------------- --------------- ------- ------- ------------- -------
  Age                                  1.037          1.025-1.049     0.000   1.045   1.029-1.062   0.000
  Gender (male *vs* female)            1.128          0.887-1.434     0.327   1.235   0.852-1.790   0.265
  Tumor size                           1.018          0.996-1.039     0.000   1.003   0.999-1.008   0.173
  Primary site (head *vs* body-tail)   1.734          1.311-2.294     0.000   1.197   0.825-1.736   0.345
  Grade (I + II *vs* III + IV)         0.570          0.443-0.734     0.104   0.490   0.333-0.721   0.000

Multivariate analysis was done with Cox proportional hazard regression model.

DISCUSSION
==========

As one of the most lethal human cancers, pancreatic cancer staging is of important significance clinically. Regardless of how the AJCC definitions of pancreatic cancer staging change, the diameter of the tumor has been shown to be a strong predictor of prognosis. The current cutoff points of \> 2 but ≤ 4 and \> 4 cm have been proposed to be the sole factor governing the IB and IIA stages in pancreatic cancer. However, the results from the current study suggest that they are not statistically sound, since the patients with stage IB and IIA cancer had similar outcomes (*P* \> 0.05). The findings reported by Burcu\[[@B17]\] contradicts our findings. Thus, further studies or more clinical data are required to evaluate the cutoff point of 4 cm tumor diameter.

In addition, moving to a different staging system has implications and comes with its challenges, such as hampered comparison with earlier data. In this study, all patients were pathologically diagnosed with stage IB pancreatic tumor according to the 6^th^ and 7^th^ edition AJCC criteria, which means the data were discrete over past decades. Therefore, further work needs to be done to evaluate the quality of the data.

Pancreatic cancer can be divided into head and body/tail cancers according to the anatomy. In this study, we found that stage IB tumors were mainly located in the head of the pancreas, while stage IIA tumors were more often located in both the tail and head of the pancreas (35.21% and 31.75%, respectively). Generally, pancreatic development begins with the formation of a ventral and a dorsal bud, which become the ventral head (lower head and uncinate process) and dorsal pancreas (upper head, body, and tail), respectively. This difference in ontogeny leads to significant differences in cell composition, blood supply, lymphatic and venous backflow, and innervations between the head and body/tail of the pancreas\[[@B18]\]. For instance, the number of islets of Langerhans is greater in the body and tail. There have been some reports showing the significance of tumor location in terms of the prognosis of pancreatic tumor. For example, in pancreatic serous cystic neoplasms and intraductal papillary mucinous neoplasms, tumor location in the head of the pancreas was independently associated with local invasiveness and recurrence\[[@B19],[@B20]\], while in pancreatic neuroendocrine tumors, tumors located at the body/tail of the pancreas were more likely to be associated with shorter progression-free survival\[[@B21]\]. Our analysis indicates that tumor location has a correlation with the prognosis in stage IB pancreatic cancer patients.

Prognostic factors combining clinical and laboratory variables with physician's estimates have been developed in recent years\[[@B22]\]. However, in this study, we just selected patients from the SEER database to analyze the prognostic factors. It is necessary for us to include more variables using our own patient database to verify the new TNM staging system.

In conclusion, our analysis demonstrates that more patients tend to be stage IB rather than stage IIA when they are diagnosed. Overall survival is mainly associated with age and primary site for stage IB patients, while for stage IIA patients, age and grade are the independent prognostic factors. The common independent prognostic factor for both patient groups is age. However, the survival time of stage IB and IIA patients has no significant difference. The results suggest that the new AJCC criteria need further evaluation.
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